<DOC>
	<DOC>NCT00223925</DOC>
	<brief_summary>Cytomegalovirus (CMV) infections remain a significant problem following various types of transplants that are associated with strong immunosuppressive therapy. Maribavir is a new oral anti-CMV drug with a novel mechanism of action compared to currently available anti-CMV drugs. This study will test the safety and anti-CMV activity of different doses of maribavir when given as CMV prophylaxis following stem cell transplants.</brief_summary>
	<brief_title>Maribavir for Prevention of CMV After Stem Cell Transplants</brief_title>
	<detailed_description />
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<criteria>Allogeneic stem cell transplant recipient Recipient CMV seropositive Have transplant engraftment Able to swallow tablets CMV organ disease HIV infection Use of other antiCMV therapy posttransplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Stem cell transplantation</keyword>
	<keyword>Allogeneic transplantation</keyword>
</DOC>